New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high ...

Protagonist Therapeutics (PTGX) announced new icotrokinra data from a subgroup analysis of ICONIC-LEAD, the first ever Phase 3 registrational ...

As an experienced pediatric subspecialist, she has focused her efforts on improving the unmet need for safe and effective treatment for children with psoriasis and eczemas. She served as the first ...

Recent research captures more evidence on the psoriasis–type 2 diabetes link and attempts to pinpoint the possible genetic and pathophysiologic mechanisms underlying this connection. This study ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...